Astra agrees proton pump inhibitor deal for Japan
29th Oct 2010 07:02
AstraZeneca will receive a $100m upfront payment from Daiichi Sankyo after agreeing a deal for the co-promotion and supply of Nexium, a proton pump inhibitor, in Japan. The Anglo-Swedish drugs giant will co-promote the product once it is approved for use in Japan, making and developing the product,
Read moreFriday tips round-up: Shell, Aggreko, Croda...
29th Oct 2010 06:48
Earlier this year, Royal Dutch Shell unveiled its new strategy to return to growth after pedestrian trading for many years. Yesterday's third-quarter numbers show that the company might just manage to pull off its ambitious plans, as quarterly output rose 5%. It is trading on a December 2010 earni
Read moreLondon close: Blue chips can't sustain early gains
28th Oct 2010 16:30
After going into a slump just ahead of midday, Footsie picked up over the lunch time session, helped by expectations of a firm start on Wall Street. The Anglo-Dutch oil giant Royal Dutch Shell grew earnings by 18% in the third quarter compared with a year ago, while the underlying figure rocketed
Read moreLondon afternoon: Stuck in consolidation mode
28th Oct 2010 14:53
After going into a slump just ahead of midday, Footsie picked up over the lunch time session, helped by expectations of a firm start on Wall Street. The Anglo-Dutch oil giant Royal Dutch Shell grew earnings by 18% in the third quarter compared with a year ago, while the underlying figure rocketed
Read moreBroker tips: Astra, Sportingbet, Blacks Leisure
28th Oct 2010 13:17
The market had expected the third quarter would be a tough one for AstraZeneca and so it proved. Company revenues declined by 3.7% from a year earlier to $7,898m, but topped market expectations of $7,830, though they failed to meet Panmure Gordon's expectations of $7,961m. Core earnings per share
Read moreFTSE 100 movers: ARM recovers
28th Oct 2010 12:57
Footsie is moving ahead today thanks to a wide range of companies. Chip designer ARM is clawing back some of its recent losses. Vodafone has spent another £21.7m on buying back shares. That takes the total spent since 16 September to £464.5m. The share price has risen by more than 8% in the past
Read moreBroker snap: Panmure still convinced of Astra's appeal
28th Oct 2010 12:14
The market had expected the third quarter would be a tough one for AstraZeneca and so it proved. Company revenues declined by 3.7% from a year earlier to $7,898m, but topped market expectations of $7,830, though they failed to meet Panmure Gordon's expectations of $7,961m. Core earnings per share
Read moreLondon midday: Good morning for blue chips
28th Oct 2010 12:06
London has enjoyed a strong morning with gains widespread following Shell's reassuring figures. The Anglo-Dutch grew earnings by 18% in the third quarter compared with a year ago, while the underlyng figure rocketed 88% to $4.93bn, well ahead of market forecasts. Earnings, on a current cost of sup
Read moreSector movers: Telecoms in demand
28th Oct 2010 11:27
Mobile Telecommunications has had a good reception Thursday, with heavyweight Vodafone, ably supported by Inmarsat and minnow Mobile Streams. Big gun AstraZeneca is dragging down Pharmaceuticals & Biotechnology. Earlier today it reported a bigger than expected 4% drop in third quarter sales to $7.9
Read moreLondon open: Footsie looks to end losing streak
28th Oct 2010 08:15
Stocks have taken their cue from Wall Street, which recovered in late trade Wednesday, and are helped by a fight back at ARM Holdings and buoyant miners. Royal Dutch Shell grew earnings by 18% in the third quarter compared with a year ago, while the figure excluding big one-off items rocketed 88% t
Read moreLondon pre-open: Shell shines
28th Oct 2010 07:42
London looks set to bounce back at the outset after two days of falls, encouraged by Wall Street's late surge yesterday. City sources predict the FTSE 100 will open up 38 points from previous close of 5,646. Royal Dutch Shell grew earnings by 18% in the third quarter compared with a year ago, while
Read moreAstra's underlying profit dips 10%
28th Oct 2010 07:05
Third quarter sales for drugs giant AstraZeneca were much as the market had anticipated, with competition from generic alternatives to its drugs denting sales in the US. Revenue in the third quarter eased 4%, or 2% using constant exchange rates (CER), to $7,898m from $8,200m a year earlier. Repor
Read moreThursday preview: Shell, Astra, Croda
27th Oct 2010 16:23
Royal Dutch Shell kept its head down while long time rival BP was being pilloried for the Gulf of Mexico oil disaster, but it is due to take centre stage on Thursday when it announces its third quarter figures and kicks off the oil company reporting season. Charles Stanley has pencilled in $4.5bn f
Read moreWeek ahead: Shell, AstraZeneca, British Airways...
22nd Oct 2010 12:48
After all of the spending review excitement of the past week it's back to the bread and butter of company announcements with some big names rolling out numbers. If the much stronger-than expected US earnings season is a guide, there could be pleasing news on the way especially among manufacturers a
Read moreLondon close: Footsie limps higher
11th Oct 2010 16:38
Footsie closed just a few points higher Monday after a sluggish day's trading that saw the leading share index fluctuating in a narrow range just above the zero mark. Oil services group Petrofac firmed on the back of a lucrative contract win. The government of Sharjah has appointed the company t
Read more